{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T06:56:58Z","timestamp":1794898618286,"version":"4.9.1"},"reference-count":81,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,17]],"date-time":"2024-04-17T00:00:00Z","timestamp":1713312000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","diabetesresearchclinicalpractice.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.diabres.2024.111675","type":"journal-article","created":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T16:59:19Z","timestamp":1713286759000},"page":"111675","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"special_numbering":"C","title":["Incretin-based investigational therapies for the treatment of MASLD\/MASH"],"prefix":"10.1016","volume":"211","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3676-5051","authenticated-orcid":false,"given":"Bram","family":"Brouwers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Girish","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1ngel","family":"Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonard C","family":"Glass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark L","family":"Hartman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.diabres.2024.111675_b0005","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1002\/hep.30251","article-title":"Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis","volume":"69","author":"Younossi","year":"2019","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.diabres.2024.111675_b0010","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/nrgastro.2016.147","article-title":"NAFLD and diabetes mellitus","volume":"14","author":"Tilg","year":"2017","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"12","key":"10.1016\/j.diabres.2024.111675_b0015","doi-asserted-by":"crossref","first-page":"4753","DOI":"10.1210\/jc.2006-0587","article-title":"Review: the role of insulin resistance in nonalcoholic fatty liver disease","volume":"91","author":"Utzschneider","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"10.1016\/j.diabres.2024.111675_b0020","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","article-title":"Mechanisms of NAFLD development and therapeutic strategies","volume":"24","author":"Friedman","year":"2018","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.diabres.2024.111675_b0025","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"Design and validation of a histological scoring system for nonalcoholic fatty liver disease","volume":"41","author":"Kleiner","year":"2005","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.diabres.2024.111675_b0030","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1055\/s-2001-12926","article-title":"Clinical features and natural history of nonalcoholic steatosis syndromes","volume":"21","author":"Falck-Ytter","year":"2001","journal-title":"Semin Liver Dis"},{"issue":"1","key":"10.1016\/j.diabres.2024.111675_b0035","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1053\/gast.2002.34168","article-title":"Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma","volume":"123","author":"Bugianesi","year":"2002","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.diabres.2024.111675_b0040","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1002\/hep.26717","article-title":"Extrahepatic complications of nonalcoholic fatty liver disease","volume":"59","author":"Armstrong","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.diabres.2024.111675_b0045","article-title":"A multi-society Delphi consensus statement on new fatty liver disease nomenclature","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.diabres.2024.111675_b0050","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.diabres.2024.111675_b0055","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/hep.23276","article-title":"Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis","volume":"51","author":"Promrat","year":"2010","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.diabres.2024.111675_b0060","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2015.04.005","article-title":"Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis","volume":"149","author":"Vilar-Gomez","year":"2015","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.diabres.2024.111675_b0065","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.diabres.2024.111675_b0070","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1053\/j.gastro.2020.06.006","article-title":"Bariatric surgery provides long-term resolution of nonalcoholic steatohepatitis and regression of fibrosis","volume":"159","author":"Lassailly","year":"2020","journal-title":"Gastroenterology"},{"issue":"20","key":"10.1016\/j.diabres.2024.111675_b0075","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1001\/jama.2021.19569","article-title":"Association of bariatric surgery with major adverse liver and cardiovascular outcomes in patients with biopsy-proven nonalcoholic steatohepatitis","volume":"326","author":"Aminian","year":"2021","journal-title":"JAMA"},{"issue":"13","key":"10.1016\/j.diabres.2024.111675_b0080","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1001\/jama.2019.14231","article-title":"Association of metabolic surgery with major adverse cardiovascular outcomes in patients with type 2 diabetes and obesity","volume":"322","author":"Aminian","year":"2019","journal-title":"JAMA"},{"issue":"10019","key":"10.1016\/j.diabres.2024.111675_b0085","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study","volume":"387","author":"Armstrong","year":"2016","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.diabres.2024.111675_b0090","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.diabres.2024.111675_b0095","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1002\/hep.32204","article-title":"Cirrhosis regression is associated with improved clinical outcomes in patients with nonalcoholic steatohepatitis","volume":"75","author":"Sanyal","year":"2022","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.diabres.2024.111675_b0100","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S2468-1253(23)00068-7","article-title":"Semaglutide 2\u00b74 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial","volume":"8","author":"Loomba","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.diabres.2024.111675_b0105","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/jmri.1880050311","article-title":"Proton MR spectroscopy in quantitative in vivo determination of fat content in human liver steatosis","volume":"5","author":"Longo","year":"1995","journal-title":"J Magn Reson Imaging"},{"issue":"4","key":"10.1016\/j.diabres.2024.111675_b0110","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1002\/hep.27647","article-title":"Ezetimibe for the treatment of nonalcoholic steatohepatitis: assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial (MOZART trial)","volume":"61","author":"Loomba","year":"2015","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.diabres.2024.111675_b0115","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1002\/hep.29797","article-title":"Noninvasive, quantitative assessment of liver fat by MRI-PDFF as an endpoint in NASH trials","volume":"68","author":"Caussy","year":"2018","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.diabres.2024.111675_b0120","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1148\/radiol.13121360","article-title":"Hepatic steatosis: quantification by proton density fat fraction with MR imaging versus liver biopsy","volume":"267","author":"Idilman","year":"2013","journal-title":"Radiology"},{"issue":"11","key":"10.1016\/j.diabres.2024.111675_b0125","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1016\/j.cgh.2020.08.061","article-title":"Change in MRI-PDFF and histologic response in patients with nonalcoholic steatohepatitis: a systematic review and meta-analysis","volume":"19","author":"Stine","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.diabres.2024.111675_b0130","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1136\/gutjnl-2021-324264","article-title":"Clinical utility of 30% relative decline in MRI-PDFF in predicting fibrosis regression in non-alcoholic fatty liver disease","volume":"71","author":"Tamaki","year":"2022","journal-title":"Gut"},{"issue":"5","key":"10.1016\/j.diabres.2024.111675_b0135","doi-asserted-by":"crossref","first-page":"e3292","DOI":"10.1002\/dmrr.3292","article-title":"Efficacy of exenatide and insulin glargine on nonalcoholic fatty liver disease in patients with type 2 diabetes","volume":"36","author":"Liu","year":"2020","journal-title":"Diabetes Metab Res Rev"},{"issue":"9","key":"10.1016\/j.diabres.2024.111675_b0140","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1111\/dom.12680","article-title":"Exenatide decreases liver fat content and epicardial adipose tissue in patients with obesity and type 2 diabetes: a prospective randomized clinical trial using magnetic resonance imaging and spectroscopy","volume":"18","author":"Dutour","year":"2016","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"10.1016\/j.diabres.2024.111675_b0145","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1007\/s00592-014-0638-3","article-title":"Effects of exenatide, insulin, and pioglitazone on liver fat content and body fat distributions in drug-naive subjects with type 2 diabetes","volume":"51","author":"Bi","year":"2014","journal-title":"Acta Diabetol"},{"issue":"11","key":"10.1016\/j.diabres.2024.111675_b0150","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1007\/s00125-020-05265-7","article-title":"Effect of dulaglutide on liver fat in patients with type 2 diabetes and NAFLD: randomised controlled trial (D-LIFT trial)","volume":"63","author":"Kuchay","year":"2020","journal-title":"Diabetologia"},{"key":"10.1016\/j.diabres.2024.111675_b0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2020.108487","article-title":"Liraglutide or insulin glargine treatments improves hepatic fat in obese patients with type 2 diabetes and nonalcoholic fatty liver disease in twenty-six weeks: a randomized placebo-controlled trial","volume":"170","author":"Guo","year":"2020","journal-title":"Diabetes Res Clin Pract"},{"issue":"2","key":"10.1016\/j.diabres.2024.111675_b0160","first-page":"407","article-title":"Effect of liraglutide therapy on liver fat content in patients with inadequately controlled type 2 diabetes: the lira-NAFLD study","volume":"102","author":"Petit","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"10.1016\/j.diabres.2024.111675_b0165","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1111\/1753-0407.12555","article-title":"Randomized trial comparing the effects of gliclazide, liraglutide, and metformin on diabetes with non-alcoholic fatty liver disease","volume":"9","author":"Feng","year":"2017","journal-title":"J Diabetes"},{"issue":"12","key":"10.1016\/j.diabres.2024.111675_b0170","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1111\/dom.13007","article-title":"Comparative effects of liraglutide 3 mg vs structured lifestyle modification on body weight, liver fat and liver function in obese patients with non-alcoholic fatty liver disease: a pilot randomized trial","volume":"19","author":"Khoo","year":"2017","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"10.1016\/j.diabres.2024.111675_b0175","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1111\/liv.14065","article-title":"Randomized trial comparing effects of weight loss by liraglutide with lifestyle modification in non-alcoholic fatty liver disease","volume":"39","author":"Khoo","year":"2019","journal-title":"Liver Int"},{"issue":"12","key":"10.1016\/j.diabres.2024.111675_b0180","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1007\/s00125-016-4100-7","article-title":"Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial","volume":"59","author":"Smits","year":"2016","journal-title":"Diabetologia"},{"issue":"8","key":"10.1016\/j.diabres.2024.111675_b0185","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1089\/met.2022.0014","article-title":"Effect of 5:2 fasting diet on liver fat content in patients with Type 2 diabetic with nonalcoholic fatty liver disease","volume":"20","author":"Xiao","year":"2022","journal-title":"Metab Syndr Relat Disord"},{"issue":"7","key":"10.1016\/j.diabres.2024.111675_b0190","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.2337\/dc14-2548","article-title":"Effects of insulin glargine and liraglutide therapy on liver fat as measured by magnetic resonance in patients with type 2 diabetes: a randomized trial","volume":"38","author":"Tang","year":"2015","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.diabres.2024.111675_b0195","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1002\/hep.30320","article-title":"Liraglutide, sitagliptin, and insulin glargine added to metformin: the effect on body weight and intrahepatic lipid in patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease","volume":"69","author":"Yan","year":"2019","journal-title":"Hepatology"},{"issue":"9","key":"10.1016\/j.diabres.2024.111675_b0200","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1111\/apt.16608","article-title":"Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non-alcoholic fatty liver disease assessed by magnetic resonance imaging","volume":"54","author":"Flint","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.diabres.2024.111675_b0205","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1111\/apt.15153","article-title":"Consensus: guidelines: best practices for detection, assessment and management of suspected acute drug-induced liver injury during clinical trials in patients with nonalcoholic steatohepatitis","volume":"49","author":"Regev","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"issue":"7","key":"10.1016\/j.diabres.2024.111675_b0210","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1016\/j.cgh.2019.10.041","article-title":"Changes in liver stiffness, measured by magnetic resonance elastography, associated with hepatic decompensation in patients with primary sclerosing cholangitis","volume":"18","author":"Eaton","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.diabres.2024.111675_b0215","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1002\/hep.30974","article-title":"Clinical utility of an increase in magnetic resonance elastography in predicting fibrosis progression in nonalcoholic fatty liver disease","volume":"71","author":"Ajmera","year":"2020","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.diabres.2024.111675_b0220","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1002\/hep.27362","article-title":"Magnetic resonance elastography predicts advanced fibrosis in patients with nonalcoholic fatty liver disease: a prospective study","volume":"60","author":"Loomba","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.diabres.2024.111675_b0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102310","article-title":"FibroScan-aspartate aminotransferase (FAST) score for monitoring histological improvement in non-alcoholic steatohepatitis activity during semaglutide treatment: post-hoc analysis of a randomised, double-blind, placebo-controlled, phase 2b trial","volume":"66","author":"Wai-Sun Wong","year":"2023","journal-title":"EClinicalMedicine"},{"issue":"9","key":"10.1016\/j.diabres.2024.111675_b0230","doi-asserted-by":"crossref","first-page":"e0238717","DOI":"10.1371\/journal.pone.0238717","article-title":"Accuracy of cytokeratin 18 (M30 and M65) in detecting non-alcoholic steatohepatitis and fibrosis: A systematic review and meta-analysis","volume":"15","author":"Lee","year":"2020","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.diabres.2024.111675_b0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2014.05.010","article-title":"Relationship between changes in serum levels of keratin 18 and changes in liver histology in children and adults with nonalcoholic fatty liver disease","volume":"12","author":"Vuppalanchi","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.diabres.2024.111675_b0240","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/hep.21984","article-title":"Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers","volume":"47","author":"Guha","year":"2008","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.diabres.2024.111675_b0245","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.jhep.2020.03.036","article-title":"Enhanced liver fibrosis test for the non-invasive diagnosis of fibrosis in patients with NAFLD: a systematic review and meta-analysis","volume":"73","author":"Vali","year":"2020","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.diabres.2024.111675_b0250","first-page":"303","article-title":"The neo-epitope specific PRO-C3 ELISA measures true formation of type III collagen associated with liver and muscle parameters","volume":"5","author":"Nielsen","year":"2013","journal-title":"Am J Transl Res"},{"issue":"2","key":"10.1016\/j.diabres.2024.111675_b0255","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/liv.12700","article-title":"Plasma Pro-C3 (N-terminal type III collagen propeptide) predicts fibrosis progression in patients with chronic hepatitis C","volume":"35","author":"Nielsen","year":"2015","journal-title":"Liver Int"},{"issue":"6","key":"10.1016\/j.diabres.2024.111675_b0260","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1002\/hep.21178","article-title":"Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection","volume":"43","author":"Sterling","year":"2006","journal-title":"Hepatology"},{"issue":"15","key":"10.1016\/j.diabres.2024.111675_b0265","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11154394","article-title":"Non-invasive detection of fibrotic NASH in NAFLD Patients with low or intermediate FIB-4","volume":"11","author":"John","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.diabres.2024.111675_b0270","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.molmet.2018.09.009","article-title":"LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept","volume":"18","author":"Coskun","year":"2018","journal-title":"Mol Metab"},{"issue":"3","key":"10.1016\/j.diabres.2024.111675_b0275","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.diabres.2024.111675_b0280","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes","volume":"385","author":"Fr\u00edas","year":"2021","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.diabres.2024.111675_b0285","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1080\/17446651.2023.2184796","article-title":"An update on tirzepatide for the management of type 2 diabetes: a focus on the phase 3 clinical development program","volume":"18","author":"Fr\u00edas","year":"2023","journal-title":"Expert Rev Endocrinol Metab"},{"key":"10.1016\/j.diabres.2024.111675_b0290","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(23)01200-X","article-title":"Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial","author":"Garvey","year":"2023","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.diabres.2024.111675_b0295","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.2337\/dc19-1892","article-title":"Effects of novel dual GIP and GLP-1 receptor agonist tirzepatide on biomarkers of nonalcoholic steatohepatitis in patients with Type 2 diabetes","volume":"43","author":"Hartman","year":"2020","journal-title":"Diabetes Care"},{"issue":"10160","key":"10.1016\/j.diabres.2024.111675_b0300","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1016\/S0140-6736(18)32260-8","article-title":"Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial","volume":"392","author":"Frias","year":"2018","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.diabres.2024.111675_b0305","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.2337\/dc18-2578","article-title":"Use of plasma fragments of propeptides of type III, V, and VI procollagen for the detection of liver fibrosis in type 2 diabetes","volume":"42","author":"Bril","year":"2019","journal-title":"Diabetes Care"},{"issue":"10300","key":"10.1016\/j.diabres.2024.111675_b0310","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S0140-6736(21)01443-4","article-title":"Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial","volume":"398","author":"Ludvik","year":"2021","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.diabres.2024.111675_b0315","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S2213-8587(22)00070-5","article-title":"Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial","volume":"10","author":"Gastaldelli","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.diabres.2024.111675_b0320","doi-asserted-by":"crossref","first-page":"649","DOI":"10.3389\/fendo.2018.00649","article-title":"Future perspectives on GLP-1 receptor agonists and GLP-1\/glucagon receptor co-agonists in the treatment of NAFLD","volume":"9","author":"Seghieri","year":"2018","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.diabres.2024.111675_b0325","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.mehy.2015.10.029","article-title":"Involvement of steatosis-induced glucagon resistance in hyperglucagonaemia","volume":"86","author":"Suppli","year":"2016","journal-title":"Med Hypotheses"},{"issue":"12","key":"10.1016\/j.diabres.2024.111675_b0330","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1111\/dom.12735","article-title":"Robust anti-obesity and metabolic effects of a dual GLP-1\/glucagon receptor peptide agonist in rodents and non-human primates","volume":"18","author":"Henderson","year":"2016","journal-title":"Diabetes Obes Metab"},{"issue":"10140","key":"10.1016\/j.diabres.2024.111675_b0335","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1016\/S0140-6736(18)30726-8","article-title":"MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study","volume":"391","author":"Ambery","year":"2018","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.diabres.2024.111675_b0340","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.2337\/dc20-2151","article-title":"Effects of cotadutide on metabolic and hepatic parameters in adults with overweight or obesity and type 2 diabetes: A 54-week randomized phase 2b study","volume":"44","author":"Nahra","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2024.111675_b0345","doi-asserted-by":"crossref","first-page":"S54","DOI":"10.1016\/S0168-8278(23)00517-2","article-title":"Pemvidutide, a glp-1\/glucagon dual receptor agonist, significantly reduces liver fat, fibro-inflammation, and body weight in patients with non-alcoholic fatty liver disease: a 24-week multicenter, randomized, double-blind, placebo-controlled trial","volume":"78","author":"Harrison","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.diabres.2024.111675_b0350","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2023.05.013","article-title":"A Phase 2a active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with nonalcoholic fatty liver disease","author":"Romero-G\u00f3mez","year":"2023","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.diabres.2024.111675_b0355","doi-asserted-by":"crossref","first-page":"e12432","DOI":"10.1111\/cob.12432","article-title":"Efficacy and safety of glucagon-like peptide-1\/glucagon receptor co-agonist JNJ-64565111 in individuals with obesity without type 2 diabetes mellitus: a randomized dose-ranging study","volume":"11","author":"Alba","year":"2021","journal-title":"Clin Obes"},{"issue":"2","key":"10.1016\/j.diabres.2024.111675_b0360","doi-asserted-by":"crossref","first-page":"e12433","DOI":"10.1111\/cob.12433","article-title":"Efficacy and safety of glucagon-like peptide-1\/glucagon receptor co-agonist JNJ-64565111 in individuals with type 2 diabetes mellitus and obesity: a randomized dose-ranging study","volume":"11","author":"Di Prospero","year":"2021","journal-title":"Clin Obes"},{"key":"10.1016\/j.diabres.2024.111675_b0365","doi-asserted-by":"crossref","first-page":"S124","DOI":"10.1016\/S0168-8278(20)30765-0","article-title":"HM15211, a novel GLP-1\/GIP\/Glucagon triple-receptor co-agonist significantly reduces liver fat and body weight in obese subjects with non-alcoholic fatty liver disease: a Phase 1b\/2a, multicenter, randomized, placebo-controlled trial","volume":"73","author":"Abdelmalek","year":"2020","journal-title":"J Hepatol"},{"issue":"6","key":"10.1016\/j.diabres.2024.111675_b0370","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa2301972","article-title":"Triple-hormone-receptor agonist retatrutide for obesity - a phase 2 trial","volume":"389","author":"Jastreboff","year":"2023","journal-title":"N Engl J Med"},{"issue":"Suppl. 1","key":"10.1016\/j.diabres.2024.111675_b0375","article-title":"Triple hormone receptor agonist retatrutide resolves steatosis in >85 % of subjects with NAFLD and obesity in association with improved metabolic health","volume":"78","author":"Sanyal","year":"2023","journal-title":"Hepatology"},{"issue":"10","key":"10.1016\/j.diabres.2024.111675_b0380","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1136\/gutjnl-2019-319104","article-title":"Combination therapy for non-alcoholic steatohepatitis: rationale, opportunities and challenges","volume":"69","author":"Dufour","year":"2020","journal-title":"Gut"},{"issue":"12","key":"10.1016\/j.diabres.2024.111675_b0385","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1038\/oby.2011.152","article-title":"Effects of combined exenatide and pioglitazone therapy on hepatic fat content in type 2 diabetes","volume":"19","author":"Sathyanarayana","year":"2011","journal-title":"Obesity (Silver Spring)"},{"issue":"1","key":"10.1016\/j.diabres.2024.111675_b0390","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/hep.31205","article-title":"Cilofexor, a nonsteroidal FXR agonist, in patients with noncirrhotic NASH: A phase 2 randomized controlled trial","volume":"72","author":"Patel","year":"2020","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.diabres.2024.111675_b0395","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1053\/j.gastro.2018.07.027","article-title":"GS-0976 reduces hepatic steatosis and fibrosis markers in patients with nonalcoholic fatty liver disease","volume":"155","author":"Loomba","year":"2018","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.diabres.2024.111675_b0400","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/hep.31622","article-title":"Combination therapies including cilofexor and firsocostat for bridging fibrosis and cirrhosis attributable to NASH","volume":"73","author":"Loomba","year":"2021","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.diabres.2024.111675_b0405","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jhep.2022.04.003","article-title":"Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: a randomised, open-label phase II trial","volume":"77","author":"Alkhouri","year":"2022","journal-title":"J Hepatol"}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822724005850?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822724005850?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T02:19:19Z","timestamp":1715221159000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168822724005850"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":81,"alternative-id":["S0168822724005850"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2024.111675","relation":{},"ISSN":["0168-8227"],"issn-type":[{"value":"0168-8227","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Incretin-based investigational therapies for the treatment of MASLD\/MASH","name":"articletitle","label":"Article Title"},{"value":"Diabetes Research and Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabres.2024.111675","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Eli Lilly and Company. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"111675"}}